Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: La Jolla, California • Pasadena, California • Tampa, Florida + 7 more

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 1,571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 27
States / cities: Los Angeles, California • Torrance, California • Denver, Colorado + 16 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer, Head and Neck Neoplasms
Interventions: M7824, N803, TriAd vaccine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Indinavir sulfate, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Respiratory Failure, Ventilatory Failure, COVID-19, Pneumonia, ARDS, Human
Interventions: AirGo Respiratory Monitor; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Candidiasis, Oral, HIV Infections
Interventions: L-743,872; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rahway, New Jersey

Conditions: Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
Interventions: PEG -Intron, Colchicine; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 49
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 39 more

Conditions: Chronic Hepatitis C Infection
Interventions: Fuzheng Huayu, Placebo; Drug
Lead sponsor: Tarek Hassanein; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Coronado, California • Palo Alto, California • Pasadena, California + 5 more

Conditions: HIV Infections
Interventions: raltegravir; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 16 Years and older
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Glastonbury, Connecticut + 9 more

Conditions: HIV Infection
Interventions: Nelfinavir mesylate, 625 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Jacksonville, Florida • Miami, Florida • Metairie, Louisiana + 2 more

Conditions: HIV/AIDS, Vitamin D Deficiency, Smoker Lung
Interventions: Vitamin D3 450,000 IU orally; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hepatitis C, Liver Disease
Interventions: Alisporivir, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Bakersfield, California • Lancaster, California • San Diego, California + 6 more

Conditions: Non-infectious, Non-necrotizing Anterior Scleritis
Interventions: Dexamethasone Phosphate Ophthalmic Solution (EGP-437), Dexamethasone phosphate ophthalmic solution; Drug
Lead sponsor: John Kempen; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: San Francisco, California • Miami, Florida • Baltimore, Maryland + 3 more

Conditions: Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 22
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions: Clofazimine Inhalation Suspension, Placebo; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 54
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more

Conditions: Hemophilia A
Interventions: BAY2599023 (DTX201); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Little Rock, Arkansas • Ann Arbor, Michigan • Madison, Wisconsin

Conditions: Chronic Hepatitis C
Interventions: statin; Drug
Lead sponsor: Bader, Ted, M.D.; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
Interventions: CMVpp65-A*0201 peptide vaccine, Placebo, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Duarte, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Liver Disease
Interventions: sofosbuvir/ledipasvir, sofosbuvir, Ribavirin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: New York, New York • Dallas, Texas

Conditions: HIV Infections
Interventions: Atazanavir, Lopinavir/Ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Chapel Hill, North Carolina

Search by objective public record fields.

Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

Study of Long-term Peg Intron vs. Colchicine in Non-responders.

Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors